Genetic Architecture And Clinical Outcomes Of The Fredrickson-Levy-Lees Dyslipoproteinemias

Thomas Gilliland, MD (1-3), Jaqueline S. Dron, PhD (1-2), Margaret Sunitha Selvaraj, PhD (1-3), Mark Trinder, BA (4-5), Kaavya Paruchuri, MD (1-3), Sarah M. Urbut, MD PhD (1-3), Sara Haidermota, BA (1-2), Rachel Bernardo, BS (1-2), Md Mesbah Uddin, PhD (1-2), Michael C. Honigberg, MD MPP (1-3), Gina Peloso, PhD (6), Pradeep Natarajan, MD, MMSc (1-3)

(1) Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA
(2) Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA
(3) Department of Medicine, Harvard Medical School, Boston, MA
(4) Centre for Heart Lung Innovation, University of British Columbia, Vancouver.
(5) Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard, Cambridge, Massachusetts.
(6) Department of Biostatistics, Boston University School of Public Health, Boston, MA

Please address correspondence to:
Pradeep Natarajan, MD, MMSc
55 Fruit Street
Boston, Massachusetts 02145
pnatarajan@mgh.harvard.edu
617-726-1843

Abstract

Background and Aims: The genetic basis and clinical relevance of the classical Fredrickson-Levy-Lees (FLL) dyslipoproteinemia classifications has not been studied in general population-based cohorts. We aimed to evaluate the phenotypic and genetic characteristics of FLL disorders.

Methods: Among UK Biobank participants free of prevalent coronary artery disease (CAD), we used blood lipids and apolipoprotein B concentrations to infer FLL classes (Types I, IIa, IIb, III, IV, and V). For each FLL class, Cox proportional hazards regression estimated risk of incident CAD. Phenome-wide association testing was performed. GWAS were performed, followed by *in silico* causal gene prioritization and heritability analyses. Prevalence of disruptive Mendelian lipid variants was assessed from whole exome sequencing.

Results: Of 450,636 individuals, 259,289 (57.5%) met criteria for a FLL dyslipoproteinemia: 63 (0.01%) type I; 40,005 (8.9%) type IIa; 94,785 (21.0%) type IIb; 13,998 (3.1%) type III; 110,389 (24.5%) type IV; and 49 (0.01%) type V. Over median 11.1 years follow-up, compared to normolipidemics the type IIb pattern conferred the highest hazard of incident CAD overall (HR 1.92, 95% CI 1.84-2.01, *P*<0.001) and in meta-analysis across matched non-HDL-C strata (HR 1.45, 95% CI 1.30-1.60). GWAS revealed 250 loci associated with FLL, of which 13 were shared across all classes; compared to GWAS of isolated lipid traits, 72 additional loci were detected. Mendelian lipid variants were rare (2%), but polygenic heritability was high, ranging from 23% (type III) to 54% (type IIb).

Conclusions: FLL classes have distinct genetic architectures yielding new insights for cardiometabolic disease beyond single lipid analyses.

46 **Keywords**
47 ApoB: apolipoprotein B
48 FLL: Fredrickson-Levy-Lees
49 GWAS: genome-wide association study
50

Introduction:

Over 50 years ago, Fredrickson, Levy, and Lees (FLL) introduced a classification scheme for lipid disorders based on patterns of circulating lipoproteins(1). In their seminal series of papers, the authors describe six dyslipoproteinemia types involving excess of one or more lipoprotein fractions. These were termed types I, IIa, IIb, III, IV, and V, reflecting chylomicron (CM) excess, low-density lipoprotein (LDL) excess, combined LDL and very low-density lipoprotein (VLDL) excess, remnant cholesterol-rich lipoprotein excess, VLDL excess, and combined CM and VLDL excess, respectively (**Table 1**). The authors observed distinguishing clinical characteristics and patterns of heritability for each disorder and hypothesized pathophysiologic mechanisms.

Owing to the cost and complexity of laboratory techniques used for diagnosis, the FLL phenotypes have been studied primarily in specialized lipid clinics and research cohorts. These settings may tend to capture extreme phenotypes, and conclusions drawn may not generalize to contemporary general populations beset with growing obesity and diabetes epidemics. Thus, the proposed clinical rationale for FLL classification beyond considering conventional lipid measures alone remains theoretical. Sniderman and colleagues developed and validated a diagnostic algorithm for the FLL disorders based on serum total cholesterol (TC), triglycerides (TG), and apolipoprotein B (apoB)(2), allowing FLL diagnosis with routine lipid measurements. Application to contemporary Western populations reveals a high prevalence of FLL dyslipoproteinemia with relationships to subclinical atherosclerosis(3,4). Associations with clinical outcomes in large contemporary cohorts are presently unknown.

Monogenic factors have largely been studied as the basis of FLL classes but comprise a very small fraction of individuals with dyslipoproteinemias. Inheritance patterns for FLL

disorders are believed to be variably monogenic, oligogenic, and polygenic, but characterizations

have largely been restricted to the former. Furthermore, phenotypic expression may depend on

the interactions between genetic and environmental factors(5)'(6). Expression of the type III

pattern in patients with *APOE2* homozygosity is modified by mutations in other lipid-related

genes(7,8) and likely requires comorbid disease or exposure – hyperinsulinemia, alcohol excess,

or the postmenopausal state(9). Further, clinical type III can occur independently of *APOE2*(10).

While the type II phenotype with isolated hypercholesterolemia (type IIa) is classically

monogenic (i.e., familial hypercholesterolemia [FH]), FH represents a very small fraction of type

II pattern(11,12). FLL type IIb is believed to be polygenic, but the genetic factors are not well

understood(6)'(13).

Here we apply the apoB-based classification scheme to a general population-based cohort

to evaluate the clinical characteristics and cardiovascular outcomes of the FLL phenotypes. We

complement our findings with genome-wide association studies of the FLL disorders and

perform unbiased phenotype association testing to glean novel insights into lipid metabolic

disturbances.

Methods

Study participants.

The UK Biobank (UKBB) is a cohort of ~500,000 volunteer participants living in the

United Kingdom at ages 40-69 years recruited across 22 sites between 2006 and 2010, with

ongoing follow up(14). Extensive genetic and phenotypic data is available as previously

described. Laboratory measurements, anthropometrics, and clinical histories were ascertained at

study enrollment. This research was conducted under UK Biobank application number 7089. All

study participants provided written and informed consent. The Mass General Brigham

Institutional Review Board approved secondary use of these data (2013P001840).

Biochemical measurement and definition of Fredrickson-Levy-Lees classes.

Among UKBB participants, non-fasting blood lipids and apoB were measured at

baseline. ApoB was quantified by immuno-turbimetric assay, TC and TG by enzymatic assay,

high-density lipoprotein cholesterol (HDL-C) by enzyme immune-inhibition assay, and direct

low-density lipoprotein cholesterol (LDL-C) by enzymatic selective protection assay, all using

the Beckman Coulter AU5800 analytical platform, as previously reported(15). The presence of

lipid-lowering medications was ascertained at baseline. Similar to prior studies, in the presence

of a statin prescription, total cholesterol (TC) was divided by 0.8 and apoB and LDL-C were

divided by 0.7(16,17).

Among 450,636 UKBB participants free of CAD at baseline, FLL phenotype was

determined by an algorithm developed by Sniderman and colleagues, which utilizes apoB, TG

and the ratios of TG/apoB and TC/apoB to group individuals into one of six dyslipoproteinemias

(**Table 1**)(2). Individuals not meeting criteria for FLL were categorized as normolipidemic.

Sensitivity analyses were performed among individuals who were not prescribed lipid-lowering

medications (including statins, ezetimibe, fibrates, or niacin) (N = 382,159).

Genotyping.

UKBB samples were genotyped using the UK Biobank Lung Exome Variant Evaluation

(UK BiLEVE) or Applied Biosystems UK Biobank Axiom Array. Genetic data was imputed

using either the Haplotype Reference Consortium panel or the UK10K + 1000 Genomes

panel(14,18).

Clinical phenotypes.

UKBB study subjects were free of CAD at the time of enrollment. The CAD definition

was based on the appearance of a qualifying International Classification of Diseases (ICD) code

corresponding to acute myocardial infarction and coronary artery revascularization, physician, or

patient report, as used previously (**Supplementary Table 1**)(19–21). Similarly, the covariates of

hypertension and type 2 diabetes were based on a combination qualifying ICD code or physician

or patient report.

We coded 1584 phenome-wide phenotypes in UKBB from both prevalent and incident

hospital episodes using ICD-9 and -10 diagnosis codes grouped into phecodes(22–24). Phecodes

that were sex-specific were coded as not applicable for the opposite sex. Clinical phenotypes

were defined using the Phecode Map 1.2 ICD-9 and ICD-10 phenotype groupings(25). ICD

codes were queried up to March 2020 in UKBB.

Monogenic dyslipidemia variant annotation

Monogenic dyslipidemia variant identification was performed on the subset of ~200,000

whole exome sequences (WES) available for UKBB participants who were also included in our

study(26).

We extracted variants disrupting genes associated with monogenic dyslipidemia

phenotypes, including high LDL-C, low HDL-C, and high TG. Each gene was defined on

whether the resultant phenotype followed an autosomal dominant (AD) or autosomal recessive

(AR) inheritance pattern. High LDL-C genes included *LDLR* (AD), *APOB* (AD), *PCSK9* (AD),

LDLRAP1 (AR), *ABCG5* (AR), and *ABCG8* (AR). Low HDL-C genes included: *APOA1* (AD),

ABCA1 (AR), and *LCAT* (AR). High TG genes included: *LPL* (AD), *APOA5* (AD), *APOC2*

(AR), *GPIBHP1* (AR), *LMF1* (AR), and *APOE* (AR). Individuals were considered as having a

consistent Mendelian lipid variant if they were either homozygous or heterozygous for the

alternative allele in AD genes, or homozygous for the alternative allele in AR genes.

Variants with minor allele frequencies of <1% and <10% were considered in AD and AR

genes, respectively. This list was further restricted based on multiple variant annotations;

variants were included if they were defined as high-confidence loss-of function by the Ensemble

Variant Effect Predictor (VEP) LOFTEE plugin, had a ClinVar interpretation of "pathogenic" or

"pathogenic/likely pathogenic" (last checked November 2021), or were predicted as "damaging"

by metaSVM(27–29). All variants were annotated following canonical gene transcripts.

Further, we determined genotypes for *APOE* (E2/E3/E4) based on allelic combinations

from rs429358 and rs7412 (where rs429358 and rs7412 are T and T, respectively, for *APOE* E2;

T and C for *APOE* E3; and C and C for *APOE* E4).

We used PLINK (version 2.0)(30) to perform variant extractions.

Statistical analysis.

For descriptive analyses, categorical variables are presented as frequencies and

proportions and compared using chi square or Fisher's exact test, and continuous variables are

presented as mean with standard deviation or median with interquartile range and compared with

Student's T-test or Wilcoxon rank sum test.

In UKBB, incident CAD was compared between FLL phenotypes using Cox proportional

hazards regression ('survival' R software package, version 3.2-13) relative to normolipidemic

individuals. The model accounted for study enrollment to March 31st, 2020. Participants were

censored if loss-to-follow-up or death occurred prior to March 31st, 2020. Covariates included

age, sex, smoking status, genotyping array, the first five principal components of genetic

ancestry, hypertension, type 2 diabetes, BMI, and statin prescription. In secondary analysis,

individuals were sub-grouped according to non-HDL-C concentration (130-160 mg/dl, 160-190

mg/dl, 190-220 mg/dl, and 220-250 mg/dl); individuals with FLL types IIa, IIb, III, and IV were

compared separately against a reference group of stratum-matched normolipidemic individuals

for incident CAD using Cox proportional hazards regression. Heterogeneity testing was used to

assess significant differences within non-HDL-C groups, and meta-analysis was performed

across non-HDL-C groups to calculate an overall FLL phenotype effect ('meta' R software

package, version 4.19-0)(31). Statistical significance was assigned at $P<0.05$.

We tested the phenome-wide associations between FLL disorders and combined

prevalent and incident hospital episode statistic phenotypes using the PheWAS version 0.99.5-4

package for R (version 4.0.2). In a single model with normolipidemics as reference, the

association between FLL class and each phecode was assessed using logistic regression with

adjustments for age, sex, genotyping array, and the first 5 principal components of genetic

ancestry. Accounting for multiple hypothesis-testing, statistical significance was assigned at

$P<3.2\text{x}10^{-5}$ (0.05/1584 phecodes).

We performed genome-wide association studies (GWAS) using REGENIE software

(version 1.0.2) across four FLL phenotypes against normolipidemic controls(32). Third-degree

related individuals (N=34828) were excluded by the KING method(33). REGENIE step 1 was

performed on UKBB array genotypes. We excluded variants with minor allele frequency (MAF)

<1%, minor allele count <100, genotype missingness >10%, or Hardy-Weinberg equilibrium p-

value >10^{-15}. Additionally, 6 samples (of 488377 used in step 1) were excluded due to genotype

missingness >10%. In REGENIE step 2, Logistic regression was performed on genotyped and

imputed variants (N=19475096) meeting MAF and imputation quality filters (MAF >=0.01%

and INFO >=0.3), with Firth correction applied to SNPs where association p-value from standard

logistic regression was <0.01. Covariates included were age, sex, genotyping array, and the first

10 principal components of ancestry. SNPs and indels with association p-values <$5x10^{-8}$ were

considered statistically significant. In a secondary analysis examining the effect of fasting status,

we repeated the above GWAS additionally adjusting for fasting time, restricted to the top

independent SNPs for each phenotype. Using LD score regression version 1.01 (restricted to

SNPs present in HapMap3), we assessed the SNP heritability and pair-wise genetic correlation of

FLL types IIa, IIb, III, and IV(34,35). We utilized a newly developed similarity-based method

for gene prioritization, Polygenic Priority Score (PoPS), to investigate protein-coding gene

contributions to each FLL phenotype(36). PoPS was performed on summary level GWAS data

for each phenotype using 1000 Genome Project as a reference(37) to yield a ranked set of

candidate causal genes.

Analyses were performed using R version 4.0.2 (R Core Team, 2020) unless otherwise

specified.

Results

Baseline characteristics of UKBB Participants.

Overall, 450,636 UKBB participants with non-missing apoB and lipids, free of prevalent

CAD, and with active participant consent were included in the analysis. Mean age was 56.3 (8.1)

years, 44.4% were male, and 94.3% were white (**Table 2**). FLL dyslipoproteinemia was

common, with 259,289 (57.5%) participants meeting criteria for one of the FLL types. The most

prevalent FLL type was type IV (110,389, 24.5% of the overall population), followed by type IIb

(94,785, 21.0%), type IIa (40,005, 8.9%), type I (63, 0.01%), and type V (49, 0.01%)

(**Supplementary Figure 1**). Mean BMI was lowest among participants without

dyslipoproteinemia (25.9 kg/m^2), intermediate in type IIa individuals (26.9 kg/m^2), and highest in

FLL types I, IIb, IV, and V (28.9, 28.9, 28.8, and 29.3 kg/m^2, respectively). Type 2 diabetes was

more common in among individuals with FLL disorders I, IIb, IV, and V – 9.5%, 2.5%, 3.3%,

and 10.2%, respectively – compared to normolipidemics or FLL disorders IIa and III – 1.4%,

1.2%, and 1.2%, respectively. Statin treatment was most common in participants with FLL types

IIa and IIb (25.1% and 24.3%, respectively), compared to 8.3% of normolipidemics. The

distribution of lipids adjusted for lipid-lowering treatment (see Methods) reflected the

assignments according to the apoB-based algorithm (**Figure 1**).

Risk of incident CAD by FLL dyslipoproteinemia class.

Over median 11.1 years of follow-up, adjusted for age, sex, smoking status, BMI,

hypertension, type 2 diabetes mellitus, statin prescription, genotyping array, and the first five

principal components of ancestry, participants with FLL type IIb had the highest risk of incident

CAD (HR 1.92, 95% CI 1.84-2.01, P<0.001) compared to normolipidemics, followed by type IIa

(1.51, 95% CI 1.42-1.61, P<0.001) and type IV (HR 1.28, 95% CI 1.22-1.34, P<0.001) (**Figure

2, Supplementary Table 2**). Type III individuals were not at statistically increased risk relative

to normolipidemics (HR 1.05, 95% CI 0.93-1.18, P=0.44). Adjusting the model further for either

apoB or non-HDL-C attenuates the effect of FLL class on incident CAD, with preservation of

increased hazard among individuals with the type IIb phenotype compared to other common FLL

classes (**Supplementary Tables 3 and 4** for models additionally adjusting for apoB and non-

HDL-C, respectively). Type III reaches nominal significance only in the model adjusted for

apoB (HR 1.08, 95% CI 1.02-1.29, P=0.02). When patients prescribed lipid-lowering

medications at baseline were excluded from the primary survival analysis, a similar pattern was

observed of increased hazard for type IIb versus the other FLL disorders against

normolipidemics (**Supplementary Table 5**).

Across strata of non-HDL-C (130-160, 160-190, 190-220, and 220-250 mg/dL), the type

IIb pattern was associated with increased risk of incident CAD compared to types IIa, III, and IV

when compared to stratum-matched normolipidemic individuals. In random-effects meta-

analysis across the non-HDL-C strata, type IIb conferred a 1.45-fold independent hazard (95%

CI 1.30-1.60) for incident CAD (Figure 3). Risk was elevated for types IV and IIa (HR 1.18,

95% CI 1.10-1.30 and HR 1.17, 95% CI 1.04-1.30, respectively) but not for type III individuals

(**Supplementary Figure 2**).

Phenome-wide association testing in UK Biobank.

Unbiased phenome-wide association testing was performed to screen for associations

between FLL classes and combined prevalent or incident phenotypes among UKBB participants,

adjusted for age, sex, genotyping array, and the first five principal components of ancestry. A

total of 1584 phenotypes were considered in the UKBB. Effect estimates (odds ratio) between

FLL type and phecode for the union of the top 50 associations for each FLL type are shown in

Supplementary Figure 3. Representative top associations across the four phenotypes are shown

in **Figure 4**. While type IIa was strongly associated with atherosclerotic cardiovascular disease

(ASCVD) phenotypes, effects were greater for type IIb, which was also accompanied by strong

associations with diabetes mellitus, liver disease, and obesity. Type IV was also similarly

associated with diabetes mellitus, liver disease, and obesity, but effects for ASCVD were less.

Type III was most strongly associated with alcohol-related disorders and malnutrition along with

liver disease but without significant associations for diabetes or CAD.

Genomic architecture of FLL dyslipoproteinemias.

Among 98,587 individuals with any FLL dyslipoproteinemia with WES, only 2,020

(2.05%) carried a disruptive variant in a monogenic dyslipidemia gene. Type IIa had the greatest

prevalence (479 of 15,309 [3.1%]) of a disruptive monogenic dyslipidemia gene, most

commonly in *LDLR* (**Supplementary Table 6, Supplementary Figure 4**). We also assessed

APOE genotype status among study participants. Notably, the *APOE*-2/2 genotype, which is

classically associated with remnant hypercholesterolemia, was markedly enriched among FLL

type III individuals (11.4% prevalence) relative to the other FLL phenotypes and was rare among

normolipidemics (0.5% prevalence) (**Supplementary Table 7, Supplementary Figure 5**).

Common variants were assessed for relevance separately for FLL types IIa, IIb, III, and

IV (types I and V were excluded due to low case counts) against normolipidemic individuals

through GWAS. Among 418603 unrelated individuals included, there were 57 with type I,

37,211 with type IIa, 88,007 with type IIb, 13,030 with type III, 102,677 with type IV, 45 with

type V, and 177,576 normolipidemics. These independent GWAS identify 77, 210, 31, and 99

variants contributing to FLL types IIa, IIb, III, and IV, respectively (**Supplementary Tables 8-**

11). Taken together, these represent a total of 250 unique genome-wide significant ($P < 5\text{x}10^{-8}$)

loci contributing to any FLL class (**Figure 5, Supplementary Table 12**). Of the total associated

loci, 13 were shared across all phenotypes (**Supplementary Table 13**), all of which are

previously described lipid-associated genes. Unique loci for types IIa, IIb, III, and IV, number

12, 97, 5, and 21, respectively (**Supplementary Figure 7, Supplementary Table 14**).

When compared to a recent GWAS of similar size in the Million Veterans Program for

individual lipid concentrations (inclusive of HDL-C, LDL-C, TC, and TG), several loci (72 of

250 [28.8%]) are novel(38). When further compared against published studies in the GWAS

Catalog(39), 14 of the total loci are not reported to be associated with any of HDL-C, LDL-C,

TG, total-C, or apoB concentrations (**Supplementary Table 15**). Examples include rs17576576,

which associates with the FLL IIa phenotype and is upstream of peroxisome proliferator-

activated receptor gamma, coactivator 1 alpha (*PPARGC1A*), and rs3856522, which associates

with the FLL IIb phenotype and is an exonic variant of ATPase homolog 2 pseudogene

(*AHSA2P*). Rs141955254 is the sole novel purported association with the Type III phenotype and

is annotated as an intergenic variant in proximity to BMP/retinoic acid inducible neural specific

1 (*BRINP1*).

Independent variants reported in the recent CARDIoGRAM-C4D Consortium CAD

GWAS meta-analysis were extracted from FLL GWAS summary statistics for each

phenotype(40). There was substantial overlap between CAD and FLL phenotype variants. Of the

genome-wide significant CAD variants extracted from FLL GWAS summary statistics, 42.8% of

variants were nominally significant at P<0.05 for type IIb (16.9% genome-wide), 32.2% for type

IIa (12.7%), 27.1% for type IV (11.4%), and 24.2% for type III (6.4%) (**Supplementary Figure**

8). Direction of effect was generally shared between CAD variants and FLL variants for

phenotypes IIa and IIb but not for phenotypes III and IV (**Supplementary Figure 9**). For

example, *APOB* locus variants increasing the risk of CAD increased the risk of FLL types IIa

and IIb but decreased the risk of phenotypes III and IV. Further, we observe that certain loci

strongly affect risk of one condition while only modestly affecting the comparator phenotype.

LPA variants have a strong influence on CAD risk but more modest influence on the FLL

phenotypes.

Polygenic priority scoring ranked protein-coding genes from the common variants

GWAS results for FLL types IIa, IIb, III, and IV using external multi-omics data.

Supplementary Figure 10 shows the union of the top 20 genetic contributors to each phenotype

according to PoPS score. *APOE* was the top-ranked gene across all phenotypes, and common

variants linked to Mendelian lipid-related genes were prioritized for all phenotypes, including

LDLR, *APOB*, *SCARB1*, and the *APOA5/A4/C3/A1* locus. *LPL* was prioritized more highly for

the hypertriglyceridemic types (i.e., IIb, III, and IV) than for type IIa. Some prioritized novel

genes are platelet derived growth factor subunit B (*PDGFB*) for type IV, BRCA1 DNA repair

associated (*BRCA1*) and beta-1,4-galactosyltransferase 1 (*B4GALT1*) for type III, and insulin

receptor substrate 1 (*IRS1*) and insulin like growth factor 1 (*IGF1*) for type IV.

LD score regression estimated heritabilities and genetic correlations among the FLL

dyslipoproteinemias (**Supplementary Figure 11**). Observed SNP heritabilities (standard errors

[SE]) for FLL types IIa, IIb, III, and IV were 0.37 (0.1), 0.54 (0.09), 0.23 (0.29), and 0.28 (0.04),

respectively. Pairwise genetic correlations were greatest between FLL types IV and III (0.96, SE

0.03), types IIb and III (0.92, SE 0.05), and types IIb and IV (0.82, SE 0.02). The least genetic

correlations were observed between types IIa and III (0.02, SE 0.05) and IIa and IV (0.09, SE

0.01).

Sensitivity analysis: Accounting for fasting time

A minority of individuals (N=18488) fasted for greater than or equal to 8 hours prior to

baseline blood draw. Utilizing the same algorithm for FLL classification, a similar prevalence of

dyslipoproteinemia was observed: 52.3% were dyslipoproteinemic among fasting individuals

compared to 57.5% among all individuals. No significant different in the prevalences of FLL

types I, IIb, III, and V was noted, whereas types IIa and IV were less common among fasting

individuals (**Supplementary Table 17**).

Repeating GWAS with fasting time as a covariate, restricted to top independent SNPs for

each phenotype, yielded no significant different in effect estimates or association P-value for any

of the FLL disorders (**Supplementary Figure 12**).

Discussion

In a large contemporary prospective cohort, we identified individuals with one of six FLL

dyslipoproteinemias using an apoB-based classification algorithm. The prevalence of FLL

disorders was high, affecting more than half of individuals. In both primary analysis and

sensitivity analyses controlling for apoB or non-HDL-C, the type IIb phenotype conferred the

highest risk of incident CAD compared to the remaining FLL dyslipoproteinemias; importantly,

risk was also elevated for types IIa and IV in all analyses. FLL patterns exhibited diverse

phenotypic relationships, including CAD for types IIa, IIb, and IV; diabetes and liver disease for

types IIb and IV; and alcohol-related disorders and liver disease for type III. Common variant

analysis using GWAS for the four prevalent FLL disorders revealed multiple genetic

contributions to each, with novel loci detected not previously associated with individual lipids.

Monogenic dyslipidemia variants were most common among type IIa individuals, usually

affecting *LDLR*, but were rare overall (i.e., 2% prevalence), and heritability analyses highlighted

the polygenicity of the FLL phenotypes.

Our study adds to the growing evidence that FLL dyslipoproteinemias are

underrecognized in contemporary Western populations(3,4). We show that identification of

combinations of lipid derangement – as initially conceived by Fredrickson and colleagues –

allows for refinement of CAD risk, as seen with the type IIb pattern when traditional lipid

parameters are controlled for. Characterizing combinations of lipids furthermore yields distinct

patterns of cardiometabolic risk not captured by single lipid parameters. While both types IIa and

IIb are associated with CAD risk, only the latter carries significant risk independent of apoB

concentration and also carries risk for diabetes and liver disease. While current guidelines

prioritize FH, a pattern consistent with type IIa, for early preventive therapies, our observations

support extension to type IIb alongside strategies to prevent diabetes onset.

The FLL type III phenotype was not associated with CAD in our study, in contrast to

prior descriptions. As previously reported, the apoB-based scheme may be more sensitive and

less specific for severe versions of type III dysbetalipoproteinemia in comparison to

ultracentrifugation(4,41). Further, given that type III is reported to be a labile finding even

among *APOE*-2/2 carriers and likely highly influenced by environmental exposures, follow-up

time in our model may not accurately reflect total remnant cholesterol exposure. Finally, the

subclinical atherosclerosis described in contemporary cohorts with FLL type III individuals may

not manifest as clinical ASCVD in the relatively young and healthy UKBB cohort.

Our genetic studies and downstream analysis revealed several interesting findings. First,

canonical lipid loci are important contributors to each of the four most common FLL phenotypes,

but non-lipid loci appear to be associated as well. For example, we identify the *IRS1* locus as an

important contributor to both type IIb and IV phenotypes. A variant ~500kb upstream of *IRS1*

(rs2943641) is previously reported to be associated with a 35% increased risk of type 2 diabetes,

the pathophysiologic basis of which appears to be impaired insulin sensitivity (and thus

increased serum insulin) rather than altered beta cell homeostasis(42). This variant is strongly

associated with both type IIb and IV phenotypes and is in close proximity and LD with lead

CAD risk variant rs2943634(43). Thus, our strategy of combining multiple lipid derangements

allows us to link insulin resistance, lipid abnormalities, and CAD risk for a variant likely driving

CAD risk via a mechanism distinct from hypercholesterolemia. Second, while there may be

important instances of monogenic inheritance for each of the FLL types, polygenicity is a far

more common pattern of inheritance. This is consistent with prior genetic studies of individuals

with severe hypercholesterolemia (akin to FLL type IIa) and with combined hyperlipidemia (akin

to FLL type IIb)(13). In the case of the type IIb phenotype, our demonstration of high

concordance between CAD risk loci and type IIb risk loci is consistent with the finding of high

atherogenicity. Further, we find that, though concentrated among type III individuals, the *APOE*-

2/2 genotype is not necessary for its expression; rather, polygenic susceptibility appears

sufficient. Third, SNP heritability is high, and genetic correlation analysis reveals clusters of

similarity – the hypertriglyceridemic conditions (types IIb, III, and IV) share greater genetic

overlap than either types IIa and IIb or IIa with the other phenotypes.

Phenotype association testing reveals both previously reported and novel disease

associations. As expected, type IIa was associated with traditional ASCVD phenotypes, and

hypertriglyceridemic types IIb and IV were associated with obesity and diabetes mellitus, with

type IV being associated with more biliary disorders and less strongly for ASCVD, suggesting

that these may reflect a spectrum of a similar dyslipoproteinemia associated with metabolic

syndrome. Interestingly, FLL type III was associated with alcohol-related disorders and both

malnutrition and hyperalimentation. This finding suggests that the type III pattern may be related

to an exposure not well captured by these descriptors (e.g., liver disease) or simply cannot be

explained by a single genetic by exposure axis.

Combining our genetic and phenotypic findings reveals patterns of association for

specific FLL classes and highlights opportunities for precision medicine approaches for

dyslipidemia treatment. For example, we find that variants at *RBM47* are uniquely associated

with the type IIb phenotype. The *RBM47* locus is recently reported as a putative novel CAD risk

locus among individuals of Middle Eastern ancestry(44). Further, in exome sequencing of

diverse ancestry populations there was an association between the burden of deleterious variants

in *RBM47* and TG/HDL-C ratio, and specific variants have been shown to significantly alter

apoC-III concentrations(45). This may indicate that the type IIb phenotype would benefit from

apo-CIII-lowering therapies in addition to LDL-C-lowering therapies. We also found the

FAM13A locus to be uniquely associated with the type IIb phenotype (lead variant rs6824451,

OR 1.04, $P=7.84\times10^{-10}$). This variant also increased risk for the type IV phenotype, although it

did not reach genome-wide significance (OR 1.03, $P=7.48\times10^{-7}$). *FAM13A* encodes family with

sequence similarity 13 member A, which has been implicated in body fat distribution in humans

and visceral to subcutaneous adipose tissue ratio in mice via effects on adipocyte

differentiation(46); a functional genomic study in adipocytes prioritized *FAM13A* as a causal

gene in insulin resistance(47). Overall, these findings point to a common mechanism connecting

abnormal adipocyte homeostasis with lipid phenotype among hypertriglyceridemic FLL types IIb

and IV.

This study has several limitations. First, the UKBB is a predominantly European ancestry

cohort, and studies in ancestrally diverse populations are necessary to test whether these findings

generalize to non-European groups. Second, we relied on non-fasting lipids (the UKBB Biobank

standard) to assign Fredrickson class. Reassuringly, we found that when we limited the

population to those with >= 8 hour fast prior to the baseline lab draw, a similar proportion of

participants met criteria for a FLL disorder, suggesting this is simply a high prevalence

population. Further evidence of high baseline dyslipoproteinemia is that type IIa prevalence is

double that in other contemporary cohorts (8.9% versus 4-5%), despite apoB not being

significantly influenced by the post-prandial state(22,48). Importantly, though isolated

hypertriglyceridemia (FLL type IV) is classically defined in the fasting state, post-prandial

hypertriglyceridemia has equal implications for cardiovascular risk (49). Our approach of

applying the FLL framework to non-fasting samples permits clinical and genetic discovery on a

scale not feasible when restricting to fasting-only samples, and we show that genetic results are

unaffected by fasting time.

By accounting for patterns of change in multiple lipoprotein subfractions, the FLL

classification scheme describes an underlying pathophysiologic disturbance with specificity that

individual lipoprotein fractions cannot. Individuals with the type IIb pattern are at elevated risk

of ASCVD relative to other dyslipoproteinemic individuals at equivalent non-HDL-C and thus

merit intensive risk reduction and attention to the associated disease states that may contribute to

the phenotype. Differential genetic risk factors underlying the FLL types highlights opportunities

for precision medicine strategies aimed at lipid patterns beyond LDL-C alone.

Funding

Dr. Gilliland is partially supported by the National Heart, Lung, and Blood Institute T32 grant 5T32HL125232. Dr. Dron is supported by the Canadian Institute of Health Research as a Banting Postdoctoral Research Fellow. Drs. Peloso and Natarajan are supported by grants from the National Heart, Lung, and Blood Institute (R01HL142711, R01HL127564). In addition, Dr. Natarajan is supported by grants from the National Heart Lung and Blood Institute (R01HL148050, R01HL151283, R01HL148565, R01HL135242, R01HL151152), National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125782), Fondation Leducq (TNE-18CVD04), and Massachusetts General Hospital (Paul and Phyllis Fireman Endowed Chair in Vascular Medicine).

Acknowledgements

The authors would like to acknowledge and thank the staff, investigators, and participants

of the UK Biobank.

Disclosures

Dr. Natarajan reports grant support from Amgen, Apple, AstraZeneca, Boston Scientific,

and Novartis, spousal employment and equity at Vertex, consulting income from Apple,

AstraZeneca, Novartis, Genentech / Roche, Blackstone Life Sciences, Foresite Labs, and

TenSixteen Bio, and is a scientific advisor board member and shareholder of TenSixteen Bio and

geneXwell, all unrelated to this work. The other authors report no disclosures.

Data Availability

The data underlying this article were accessed from the UK Biobank under Application number 7089. UK Biobank individual-level data are available for request by application (www.ukbiobank.ac.uk).

References

1. Fredrickson DS, Levy RI, Lees RS. Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders. New England Journal of Medicine. 1967 Jan 5;276(1):34–44.

2. de Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Clin Pract Endocrinol Metab. 2008 Nov;4(11):608–18.

3. Holewijn S, Sniderman AD, den Heijer M, Swinkels DW, Stalenhoef AFH, de Graaf J. Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study. Eur J Clin Invest. 2011 Apr;41(4):423–33.

4. Sathiyakumar V, Pallazola VA, Park J, Vakil RM, Toth PP, Lazo-Elizondo M, et al. Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. Arch Med Sci. 2020;16(6):1279–87.

5. Keulen ET, Voors-Pette C, de Bruin TW. Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens. 2001 Apr;14(4 Pt 1):357–63.

6. Brouwers MCGJ, van Greevenbroek MMJ, Stehouwer CDA, de Graaf J, Stalenhoef AFH. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol. 2012 Feb 14;8(6):352–62.

7. Evans D, Seedorf U, Beil FU. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. Clin Genet. 2005 Oct;68(4):369–72.

8. Schaefer JR, Sattler AM, Hackler B, Kurt B, Hackler R, Maisch B, et al. Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor. Clin Chem. 2004 Nov;50(11):2214.

9. de Beer F, Stalenhoef AFH, Hoogerbrugge N, Kastelein JJP, Gevers Leuven JA, van Duijn CM, et al. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):294–9.

10. Breckenridge WC, Little JA, Alaupovic P, Wang CS, Kuksis A, Kakis G, et al. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 1982 Nov;45(2):161–79.

11. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016 Jun 7;67(22):2578–89.

12. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial
hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General
Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016 May
1;37(17):1384–94.

13. Gill PK, Dron JS, Berberich AJ, Wang J, McIntyre AD, Cao H, et al. Combined
hyperlipidemia is genetically similar to isolated hypertriglyceridemia. J Clin Lipidol. 2021
Feb;15(1):79–87.

14. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.

15. serum_biochemistry.pdf [Internet]. [cited 2021 Dec 2]. Available from:
https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/serum_biochemistry.pdf

16. Natarajan P, Peloso GM, Zekavat SM, Montasser M, Ganna A, Chaffin M, et al. Deep-
coverage whole genome sequences and blood lipids among 16,324 individuals. Nat
Commun. 2018 Aug 23;9(1):3391.

17. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J,
Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL
cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet. 2010 Nov 13;376(9753):1670–81.

18. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide genetic
data on ~500,000 UK Biobank participants [Internet]. Genetics; 2017 Jul [cited 2021 Sep 7].
Available from: http://biorxiv.org/lookup/doi/10.1101/166298

19. Honigberg MC, Zekavat SM, Aragam K, Finneran P, Klarin D, Bhatt DL, et al. Association
of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.
JAMA. 2019 Dec 24;322(24):2411–21.

20. Klarin D, Zhu QM, Emdin CA, Chaffin M, Horner S, McMillan BJ, et al. Genetic analysis in
UK Biobank links insulin resistance and transendothelial migration pathways to coronary
artery disease. Nat Genet. 2017 Sep;49(9):1392–7.

21. Honigberg MC, Zekavat SM, Niroula A, Griffin GK, Bick AG, Pirruccello JP, et al.
Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in
Postmenopausal Women. Circulation. 2021 Feb 2;143(5):410–23.

22. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al.
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease
associations. Bioinformatics. 2010 May 1;26(9):1205–10.

23. Wei WQ, Bastarache LA, Carroll RJ, Marlo JE, Osterman TJ, Gamazon ER, et al. Evaluating
phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide
association studies in the electronic health record. PLoS One. 2017;12(7):e0175508.

24. Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Mapping ICD-10 and ICD-10-
CM Codes to Phecodes: Workflow Development and Initial Evaluation. JMIR Med Inform.
2019 Nov 29;7(4):e14325.

25. Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Mapping ICD-10 and ICD-10-
CM Codes to Phecodes: Workflow Development and Initial Evaluation. JMIR Med Inform.
2019 Nov 29;7(4):e14325.

26. Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, et al.
Advancing human genetics research and drug discovery through exome sequencing of the
UK Biobank. Nat Genet. 2021 Jul;53(7):942–8.

27. Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3.0: A One-Stop Database of Functional
Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs. Hum
Mutat. 2016 Mar;37(3):235–41.

28. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public
archive of relationships among sequence variation and human phenotype. Nucleic Acids
Res. 2014 Jan;42(Database issue):D980-985.

29. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The
mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020
May;581(7809):434–43.

30. PLINK 2.0 [Internet]. [cited 2021 Dec 31]. Available from: https://www.cog-
genomics.org/plink/2.0/

31. Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R [Internet]. Cham: Springer
International Publishing; 2015 [cited 2021 Sep 7]. (Use R!). Available from:
http://link.springer.com/10.1007/978-3-319-21416-0

32. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al.
Computationally efficient whole-genome regression for quantitative and binary traits. Nat
Genet. 2021 Jul;53(7):1097–103.

33. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship
inference in genome-wide association studies. Bioinformatics. 2010 Nov 15;26(22):2867–
73.

34. International HapMap 3 Consortium, Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM,
Gibbs RA, et al. Integrating common and rare genetic variation in diverse human
populations. Nature. 2010 Sep 2;467(7311):52–8.

35. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group
of the Psychiatric Genomics Consortium, et al. LD Score regression distinguishes
confounding from polygenicity in genome-wide association studies. Nat Genet. 2015
Mar;47(3):291–5.

36. Weeks EM, Ulirsch JC, Cheng NY, Trippe BL, Fine RS, Miao J, et al. Leveraging polygenic
enrichments of gene features to predict genes underlying complex traits and diseases
[Internet]. Genetic and Genomic Medicine; 2020 Sep [cited 2021 Sep 7]. Available from:
http://medrxiv.org/lookup/doi/10.1101/2020.09.08.20190561

37. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang
HM, et al. A global reference for human genetic variation. Nature. 2015 Oct
1;526(7571):68–74.

38. Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, et al. Genetics of
blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat
Genet. 2018 Nov;50(11):1514–23.

39. GWAS Catalog [Internet]. [cited 2021 Dec 13]. Available from: https://www.ebi.ac.uk/gwas/

40. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Weeks EM, et al. Discovery and
systematic characterization of risk variants and genes for coronary artery disease in over a
million participants [Internet]. 2021 Jun [cited 2021 Dec 31] p. 2021.05.24.21257377.
Available from: https://www.medrxiv.org/content/10.1101/2021.05.24.21257377v1

41. Sniderman AD, de Graaf J, Thanassoulis G, Tremblay AJ, Martin SS, Couture P. The
spectrum of type III hyperlipoproteinemia. J Clin Lipidol. 2018 Dec;12(6):1383–9.

42. Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proença C, et al. Genetic
variant near IRS1 is associated with type 2 diabetes, insulin resistance and
hyperinsulinemia. Nat Genet. 2009 Oct;41(10):1110–5.

43. Genomewide Association Analysis of Coronary Artery Disease | NEJM [Internet]. [cited
2022 Jan 7]. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa072366

44. Kunji K, El -Menyar Ayman, Ullah E, Kullo I, Saad M, Al SJ. Whole genome sequencing of
a middle eastern cohort replicates known loci for coronary heart disease and identifies
potential novel ones. Journal of the American College of Cardiology. 2021 May
11;77(18_Supplement_1):13–13.

45. Sandholm N, Hotakainen R, Haukka JK, Sigfrids FJ, Dahlström EH, Antikainen A, et al.
Novel protein-altering variants associated with serum apolipoprotein and lipid levels
[Internet]. 2021 Sep [cited 2022 Jan 10] p. 2021.09.19.21263610. Available from:
https://www.medrxiv.org/content/10.1101/2021.09.19.21263610v1

46. Fathzadeh M, Li J, Rao A, Cook N, Chennamsetty I, Seldin M, et al. FAM13A affects body
fat distribution and adipocyte function. Nat Commun. 2020 Mar 19;11(1):1–13.

47. Chen Z, Yu H, Shi X, Warren CR, Lotta LA, Friesen M, et al. Functional Screening of
Candidate Causal Genes for Insulin Resistance in Human Preadipocytes and Adipocytes.
Circulation Research. 2020 Jan 31;126(3):330–46.

48. Mora S, Chang CL, Moorthy MV, Sever PS. Association of Nonfasting vs Fasting Lipid
Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes
Trial-Lipid Lowering Arm. JAMA Intern Med. 2019 Jul 1;179(7):898–905.

49. Langsted A, Nordestgaard BG. Nonfasting versus fasting lipid profile for cardiovascular risk
prediction. Pathology. 2019 Feb 1;51(2):131–41.

Figure 1. Distribution of lipids among normolipidemics and FLL classes. Lipids are

presented as mg/dL on the log(10) scale, with vertical dash marking distribution median.

Abbreviations: 'ApoB' = apolipoprotein B; 'HDL-C' = high-density lipoprotein cholesterol;

'LDL-C' = directly measured low-density lipoprotein cholesterol. ApoB, LDL-C, and total

cholesterol are corrected for baseline statin prescription, as outlined in *Methods*.

618 **Figure 2. Survival free from incident CAD according to FLL class.** Individuals with FLL

619 dyslipoproteinemias were followed for a median of 11.1 years for incident CAD. Abbreviations:

620 'CAD' = coronary artery disease; 'FLL' = Fredrickson-Levy-Lees; 'Normolipidemic' = not

621 meeting criteria for any FLL disorder.

Figure 3. FLL type IIb confers elevated CAD risk across non-HDL-C strata. Meta-analysis

of FLL type IIb effect compared to normolipidemic individuals across non-HDL-C strata.

Individuals meeting criteria for FLL type IIb were compared against stratum-matched

normolipidemic individuals across four strata of non-HDL-C. Random-effects meta-analysis

reported overall type IIb effect. Abbreviations: 'Non-HDL-C' = non-high-density lipoprotein

cholesterol; 'HR' = hazard ratio; 'CI' = confidence interval; 'N'=total individuals in a given

stratum; τ^2 = effect size variance estimated by restricted maximum likelihood method.

	IIa	IIb	III	IV	
		1.1*	1.41*		Alcohol related disorders
	1.33*	1.79*		1.47*	Angina pectoris
		1.55*	1.34*	1.85*	Cholelithiasis and cholecystitis
		1.69*	1.47*	1.74*	Chronic liver disease and cirrhosis
	0.85	1.45*	1.34	1.63*	Chronic renal failure CKD
	1.46*	1.91*		1.34*	Coronary atherosclerosis
	0.94	2.16*		2.25*	Diabetes mellitus
		2.35*	1.88*	2.14*	Gout
	1.19*	1.69*	1.19*	1.62*	Hypertension
	1.47*	2.13*		1.42*	Myocardial infarction
	1.23*	2.27*	1.44*	2.37*	Obesity
	1.52*	1.8*		1.33*	Occlusion and stenosis of precerebral arteries
	1.4*	1.54*	1.27	1.31*	Peripheral vascular disease unspecified
		0.72	2.49*	0.67	Protein calorie malnutrition
	1.24*	1.63*	1.32*	1.38*	Tobacco use disorder

Figure 4. Phenome-wide association of lipid patterns yields distinct phenotypic patterns.

PheWAS UKBB of representative phenotypes reaching phenome-wide significance (Bonferroni adjusted $P<3.2\times10^{-5}$) relative to normolipidemics. OR is presented only when nominal P value of P<0.05 is reached and are marked with "*" if reaching phenome-wide significance. Blank cells reflect exposure-phenotype associations P>0.05.

640
Figure 5. Shared and distinct genetic loci associated with FLL classes. Independent GWAS

were performed using REGENIE software for each of the common FLL phenotypes (IIa, IIb, III,

and IV) against normolipidemic individuals. Independent genome-wide significant SNPs define

+/- 500kbp loci, which are highlighted in red or blue. Red loci are unique to the phenotype, and

blue loci are shared between two or more phenotypes. X-axis reflects genomic location labeled

according to chromosome 1-22. Y-axis displays -$\log_{10}$(P-value) on the $\log_{10}$ scale.

Fredrickson-Levy-Lees class definitions					
	ApoB (mg/dL)	TG (mg/dL)	TG/apoB	TC (mg/dL) /apoB	Lipoprotein excess
Type I	<75	≧ 133	≧ 8.8	-	Chylomicrons
Type IIa	≧ 120	< 133	-	-	LDL
Type IIb	≧ 120	≧ 133	-	-	LDL and VLDL
Type III	< 120	≧ 133	< 8.8	≧ 2.4	Remnant particles
Type IV	< 120	≧ 133	< 8.8	< 2.4	VLDL
Type V	≧ 75 and < 120	≧ 133	≧ 8.8	-	Chylomicrons and VLDL

Table 1. Definition and characteristics of FLL dyslipoproteinemias. FLL disorders were

defined as previously based on apoB and TG and the ratios of TG/apoB and TC/apoB. ApoB and

TG are expressed in mg/dL for both isolated measurements and in defining the thresholds for the

ratios TG/apoB and TC/apoB. Lipoprotein excess refers to the lipoprotein particle(s) found in

excess for each phenotype. Abbreviations: 'apoB' = apolipoprotein B; 'TG' = triglycerides; 'TC'

= total cholesterol; 'LDL' = low-density lipoprotein; 'VLDL' = very low-density lipoprotein.

	All	Normolipidemic	Type I	Type IIa	Type IIb	Type III	Type IV	Type V
Number (%)	450636 (100)	191347 (42.5)	63 (0.01)	40005 (8.9)	94785 (21.0)	13998 (3.1)	110389 (24.5)	49 (0.01)
Demographics								
Age at enrollment, mean (SD), y	56.3 (8.1)	55.0 (8.3)	55.8 (8.6)	58.4 (7.3)	57.9 (7.5)	56.8 (7.7)	56.6 (8.1)	52.6 (8.6)
Male sex, n (%)	200353 (44.4)	67992 (35.5)	57 (90.5)	14991 (37.5)	48317 (51.0)	4792 (34.2)	64163 (58.1)	41 (83.7)
White, n (%)	424851 (94.3)	179080 (93.6)	59 (93.7)	37725 (94.3)	90518 (95.5)	13408 (95.8)	104015 (94.2)	46 (93.9)
Black, n (%)	7114 (1.6)	4635 (2.4)	0	847 (2.1)	635 (0.7)	128 (0.9)	869 (0.8)	0
Baseline lipids								
TC, median (IQR), mg/dl	225.8 (199.5-253.9)	208.4 (186.7-229.6)	176.4 (155.8-200.2)	265.5 (247.1-285.7)	267.4 (248.2-289.9)	221.6 (197.1-247.0)	214.5 (195.0-232.5)	230.4 (206.8-256.5)
LDL-C, median (IQR), mg/dl	143.0 (122.7-165.2)	127.6 (111.6-142.9)	90.5 (76.4-98.6)	176.2 (166.0-189.5)	178.5 (166.2-194.7)	126.1 (109.8-143.1)	137.2 (123.5-149.2)	114.2 (107.0-129.6)
HDL-C, median (IQR), mg/dl	54.5 (45.7-65.1)	60.8 (51.5-71.2)	32.7 (27.7-39.0)	60.6 (51.9-70.7)	49.5 (43.0-57.2)	64.4 (54.6-74.1)	46.9 (40.3-54.5)	32.6 (29.5-37.4)
TG, median (IQR), mg/dl	130.6 (92.3-188.9)	90.3 (72.1-109.4)	605.7 (512.2-696.1)	105.1 (88.6-119.5)	205.0 (165.5-267.6)	179.3 (151.2-235.5)	181.9 (153.6-232.7)	839.3 (786.0-903.3)
ApoB, median (IQR), mg/dl	107.3 (91.9-123.7)	95.0 (83.5-106.0)	57.4 (48.4-68.6)	129.9 (124.2-139.7)	135.4 (126.7-148.3)	86.2 (75.0-97.1)	104.7 (94.8-112.5)	84.2 (78.4-94.3)
Lipid-lowering therapy								
Statin, n (%)	62990 (14.0)	15903 (8.3)	5 (7.9)	9984 (25.0)	22888 (24.1)	522 (3.7)	13680 (12.4)	8 (16.3)
Ezetimibe, n (%)	1861 (0.4)	437 (0.2)	1 (1.6)	175 (0.4)	623 (0.6)	33 (0.2)	592 (0.5)	0
Fibrate, n (%)	1024 (0.2)	245 (0.1)	2 (3.2)	57 (0.1)	333 (0.4)	30 (0.2)	357 (0.3)	0
Niacin, n (%)	39	14	0 (0%)	1	11	2	11	0 (0%)
Any therapy, n (%)	78477 (17.4)	22718 (11.8)	9 (14.3)	11393 (28.5)	25869 (27.3)	1054 (7.5)	17426 (15.8)	8 (16.3)
Medical history								
Smoking status, n (%)	199707 (44.3)	77564 (40.5)	36 (57.1)	17689 (44.2)	46826 (49.4)	6353 (45.4)	51207 (46.4)	32 (65.3)
Never	248706 (55.2)	112920 (59.0)	27 (42.9)	22145 (55.4)	47466 (50.1)	7573 (54.1)	58559 (53.0)	16 (32.7)
Previous	152861 (33.9)	60920 (31.8)	27 (42.9)	13759 (34.4)	34631 (36.5)	4920 (35.1)	38581 (35.0)	23 (46.9)
Current	46846 (10.4)	16644 (8.7)	9 (14.3)	3930 (9.8)	12195 (12.9)	1433 (10.2)	12626 (11.4)	9 (18.4)
Hypertension, n (%)	126092 (28.0)	41155 (21.5)	30 (47.6)	11699 (29.2)	33336 (35.2)	3573 (25.5)	36279 (32.9)	20 (40.8)
Diabetes mellitus, type 2, n (%)	9316 (2.1)	2624 (1.4)	6 (9.5)	467 (1.2)	2366 (2.5)	174 (1.2)	3674 (3.3)	5 (10.2)
BMI, mean (SD), kg/m^2	27.4 (4.8)	25.9 (4.4)	28.9 (3.8)	26.9 (4.3)	28.9 (4.5)	26.9 (4.5)	28.8 (4.8)	29.3 (4.1)

Table 2. Baseline characteristics of UKBB study participants. We report demographic

characteristics, baseline lipids, lipid-lowering medication use, and relevant medical history for all

study participants ('All'), individuals not meeting criteria for an FLL disorder

('Normolipidemic'), and individuals meeting criteria for any of the six FLL dyslipoproteinemias.

Abbreviations: 'SD' = standard deviation; 'IQR' = interquartile range; 'TC' = total cholesterol;

'LDL-C' = low density lipoprotein cholesterol; 'HDL-C' = high density lipoprotein cholesterol;

'TG' = triglyceride; 'ApoB' = apolipoprotein B; 'BMI' = body-mass index.